Dr. John Cush RheumNow
3 years 4 months ago
Using Optum claims data from 2009 to 2021, they identified 524 IgG4-RD pts (mean age 56 yrs), incidence increased over time 0.78 to 1.39/100K Pt Yrs 2015 and 2019. Prevalence (1/19) was 5.3/100K Pt-Yrs, w/ mortality rate 3.42/100 Pt-Yrs (HR 2.51) https://t.co/22eIjtC7kp https://t.co/8RlEtZiX9j
Dr. John Cush RheumNow
3 years 4 months ago
Rheums! Have a rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/3atPdJwb1m https://t.co/MKbgzEi9pd
Dr. John Cush RheumNow
3 years 4 months ago
NY Times article on a Moral Crisis for Americas doctors - the corporatization of Medicine leverages finances/incomes against physican values and practice preferences. Rheum Dr. Diana Girnita presents the Direct Medical Care option for MD autonomy https://t.co/TySD8l6I94 https://t.co/ZNTx7VVRfg
Dr. John Cush RheumNow
3 years 4 months ago
EULAR 2023 Notes from Milan
https://t.co/cdmkiJmQrz https://t.co/w6UV85bFQ1
Dr. John Cush RheumNow
3 years 4 months ago
Watch: A Real Boost for Shingrix with JAKi
Dr. David Liew discusses OP0225 presented at EULAR 2023 in Milan, Italy.
https://t.co/Xgt85l6WgQ https://t.co/jPcA2GSFdm
Dr. John Cush RheumNow
3 years 4 months ago
ACR Concerned with MedPAC’s Cutting Part B Reimbursement
ACR took issue with the orgs reco to Congress to keep a 6% add-on payment for the lowest-cost drugs, reduce the add-on payment for mid-to-high-level drugs, and add a payment cap for the $$$ drugs.
https://t.co/IwZO88QThb https://t.co/GHjDwbHCCo
Dr. John Cush RheumNow
3 years 4 months ago
FAAH and FAAH-OUT - genes involved in pain perception; could these be the target of future therapies? Interesting article in FORBES bout role of FAAH and FAAH-OUT in pain. https://t.co/8FNvkVZy5R https://t.co/8Ldywt2wvq
A multinational registry analysis of rheumatoid arthritis (RA) receiving abatacept (ABA) has shown that the safety profile of ABA remains unchanged with no new or increased risks of infection or malignancy.
New recommendations on imaging for crystal-induced (gout, CPPD) arthritis (CiA) were presented at EULAR 2023 in Milan. These included 5 overarching principles & 10 recommendations on the role of imaging in making a diagnosis, monitoring, predicting, guiding therapy, and patient education in CiA.
Dr. John Cush RheumNow
3 years 4 months ago
Higher Genetic Loads Linked to Worse Systemic Lupus
A study of a large SLE cohort shows by genomic analysis, that higher wGRS is associated with earlier SLE onset, higher anti–Sm antibody positivity, lupus nephritis and more diverse lupus manifestations.
https://t.co/L8ZZEgcfNM https://t.co/elwDtDuSjP
Dr. John Cush RheumNow
3 years 4 months ago
WATCH: Update on CAR T-Cell Therapy in SLE & Autoimmune Diseases
Dr. Peter Nash reporting from EULAR 2023 in Milan, Italy.
https://t.co/EpsPtwtJJt https://t.co/QxH8Pff6RS
Dr. John Cush RheumNow
3 years 4 months ago
275 early RA pts and after 2 years, 32% reported unacceptable pain (UP). Predictors of UP best seen at 3 mos FUV (not baseline) and included #Tender Jts (not swollen), overall pain, patient global assessment, and HAQ. https://t.co/Zlv3919Ucz https://t.co/1K1zPvhUYi
Dr. John Cush RheumNow
3 years 4 months ago
EULAR Offers Tips on Psoriasis Progression to PsA
Clinicians treating patients with psoriasis should be on the lookout for certain signs that joint involvement is likely to develop, according to a new "points to consider" from the EULAR.
https://t.co/eFsWJBmzCR https://t.co/slq58tWJG6
Dr. John Cush RheumNow
3 years 4 months ago
Biosimilars Match Biologic Originators in RA
A JAMA review shows that biosimilars of adalimumab, infliximab, and etanercept were associated w/clinically equivalent treatment effects compared with their ref biologics for treatment of RA.
https://t.co/EO22ThFL5C https://t.co/wlK0e2Cg5l
